	US 12,329,775 B2
	Composition and method for treating hearing loss
Barry S. Seifer, Ann Arbor, MI (US); Louise A. Minor, Trinidad, CA (US); and Richard A. Detweiler, West Linn, OR (US)
Assigned to Soundbites Public Benefit Corporation, Ann Arbor, MI (US)
Filed by Soundbites Public Benefit Corporation, Ann Arbor, MI (US)
Filed on Aug. 9, 2024, as Appl. No. 18/799,983.
Claims priority of provisional application 63/557,066, filed on Feb. 23, 2024.
Claims priority of provisional application 63/532,714, filed on Aug. 15, 2023.
Prior Publication US 2025/0057875 A1, Feb. 20, 2025
Int. Cl. A61K 33/06 (2006.01); A61K 9/00 (2006.01); A61K 31/015 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61P 27/16 (2006.01)

CPC A61K 33/06 (2013.01) [A61K 9/0053 (2013.01); A61K 31/015 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61P 27/16 (2018.01)]

20 Claims

1. A method for restoring a level of hearing in a human subject in need thereof, wherein the method comprises orally administering to the subject a nutraceutical formulation in the form of a suspoemulsion comprising:

i) a magnesium compound comprising salts, salt complexes or chelates thereof;

ii) Vitamin C in an amount≤5,000 IU;

iii) a provitamin A carotenoid in an amount ≥8,000 ug retinol activity equivalents (RAE);

iv) Vitamin E; and

v) a nutraceutically acceptable liquid lipophilic carrier;

wherein each of i)-iv) is present in an amount, when combined together in the same formulation, to synergistically restore a level of hearing when administered to a human subject in need thereof, wherein the molar ratio of the provitamin A carotenoid, the Vitamin C, the Vitamin E, and the magnesium compound is approximately 1:7-21:6.5-9.5:110-120, and

wherein the subject has already developed hearing loss, wherein the hearing loss is not caused by a viral infection.